Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.
Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.
AIM ImmunoTech (NYSE American: AIM) has scheduled a conference call and webcast for November 15, 2024, at 8:30 AM ET to discuss their third quarter 2024 operational and financial results. The event will be led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Investors can join by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international). The webcast will be available on the company's website and archived for 90 days.
AIM ImmunoTech has filed its definitive proxy statement for the 2024 Annual Meeting, warning shareholders about an activist group's attempt to take control of the Board. The company highlights its progress with Ampligen in clinical trials, particularly in pancreatic cancer treatment. The activist group, which includes individuals with ties to securities law felons, aims to replace the entire four-member Board and seeks reimbursement of over $5 million in expenses. AIM urges shareholders to vote 'FOR' all four incumbent Board candidates to protect the company's momentum and prevent potential disruption to ongoing clinical trials.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced its participation in the 2024 Healthcare Virtual Summit, presented by Maxim Group The company's CEO, Tom Equels, will engage in a fireside chat on Wednesday, October 16th at 12:30 PM ET.
The summit will feature a series of presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology. Maxim Senior Analysts will host these sessions and plan to conduct several topical industry panels.
To attend the virtual event, interested parties need to sign up for M-Vest membership. The company encourages participants to reserve their seats through the provided link.
AIM ImmunoTech Inc. (NYSE American: AIM) has been granted U.S. patent No. 12,102,649 for using Ampligen® to treat endometriosis, a condition affecting nearly 10% of reproductive-age women. The patent covers compositions and methods using AIM's double-stranded RNA products for treating endometriosis, including recurrent cases. It also includes options for co-administration with interferons.
Endometriosis, affecting approximately 6.5 million women in the U.S., causes severe pelvic pain and fertility issues. The patented treatment offers flexible administration options for patient-specific care. Dr. Robert Edwards, Chair of Ob/Gyn/RS at UPMC, noted that a medical therapy relieving symptoms and reducing inflammation would be a significant breakthrough. AIM's CEO, Thomas K. Equels, stated that this patent strengthens their intellectual property portfolio and expands their potential to provide life-changing therapies for women with endometriosis.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced a $1.26 million registered direct offering of common stock and a concurrent private placement of warrants. The company will sell 4,653,036 shares at $0.27 per share to a single institutional investor. Additionally, AIM will issue unregistered Class C and Class D warrants to purchase up to 4,653,036 shares each, with an exercise price of $0.28. The Class C warrants expire 18 months after the initial exercise date, while Class D warrants expire after 5 years. Maxim Group is acting as the sole placement agent. The offering is made under a shelf registration statement, and a prospectus supplement will be filed with the SEC.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced that its Chief Executive Officer, Thomas K. Equels, will participate in a Virtual Investor CEO Connect segment on Wednesday, October 2, 2024, at 4:00 PM ET. The event will feature a brief presentation by Mr. Equels, followed by an interactive Q&A session.
Investors and interested parties can submit questions live during the event or pre-submit them via email to AIM@jtcir.com. A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be accessible for 90 days, starting two hours after the live presentation.
AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally well-tolerated with no severe adverse events. In the second cohort, two of three subjects also have stable disease, though not yet at the 6-month mark. Prof. Casper H.J. van Eijck noted improvements in quality of life and no toxicity, comparing favorably to typical disease progression rates. The data suggests Ampligen's potential synergy with checkpoint inhibitors for treating late-stage pancreatic cancer.
AIM ImmunoTech (NYSE American: AIM) has announced promising results from its AMP-518 Phase 2 clinical trial for Ampligen as a potential treatment for moderate-to-severe Post-COVID fatigue. The analysis showed that patients with Long COVID who received Ampligen were able to walk farther in a Six-Minute Walk Test (6MWT) compared to those who received a placebo.
Notably, subjects with a baseline 6MWT less than 205 meters showed significant improvement, with a mean increase of 139 meters compared to 91 meters in the placebo group. Based on these findings, AIM plans to focus future trials on patients with moderate or worse Long COVID-related fatigue. The company has also made key appointments to strengthen its medical team and research efforts in this area.
AIM ImmunoTech (NYSE American: AIM) announced the print publication of data analysis from a long-term Early Access Program studying Ampligen® (rintatolimod) for treating advanced pancreatic ductal adenocarcinoma (PDAC) in Clinical Cancer Research. The study, conducted at Erasmus University Medical Center, found that Ampligen enhances peripheral immune activity in pancreatic cancer patients, particularly involving type 1 conventional dendritic cells and T cells.
Key findings include:
- Increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes
- Decreased expression of immune checkpoints PD-L1 and PD-L2 post-Ampligen
- Potential for Ampligen to improve progression-free survival and overall survival
AIM ImmunoTech Inc. (NYSE American: AIM) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
Financial Results:
- Cash, cash equivalents, and marketable securities: $10.1 million as of June 30, 2024
- R&D expenses: $1.1 million for Q2 2024, down from $3.0 million in Q2 2023
- G&A expenses: $2.6 million for Q2 2024, unchanged from Q2 2023
- Net loss: $1.8 million ($0.03 per share) for Q2 2024, compared to $4.9 million ($0.10 per share) in Q2 2023
Corporate Updates:
- New positive data on Ampligen's anti-tumor potential in melanoma treatment
- Publication of results in the peer-reviewed journal Vaccines
- Continued progress in Ampligen clinical development programs
